Thursday, March 17, 2011
Repros Therapeutics Inc., of The Woodlands, Texas, dosed its first patients in a low-dose study of Proellex for uterine fibroids and endometriosis. Previous studies at a 50-mg dose were held when some subjects experienced severe liver toxicity. The new study will enroll five cohorts at doses from 1 mg to 12 mg per day, starting with the lowest cohort and not progressing to the next dose until an outside drug safety monitoring committee has reviewed the liver safety data from the previous.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.